Vimarsana
Biggest News Aggregation in the World

Page 38 - Patrick Wingrove News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Patrick Wingrove. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Patrick Wingrove Today - Breaking & Trending Today

Merck sues US government to halt Medicare drug price negotiation - Vimarsana News

Merck sues US government to halt Medicare drug price negotiation

NEW YORK (Reuters) -Merck & Co sued the U.S. government on Tuesday, seeking to halt the Medicare drug price negotiation program contained in the Inflation Reduction Act (IRA), which it argues violates the Fifth and First Amendments to the U.S. Constitution. This is the first attempt by a drugmaker to challenge the law, which the pharmaceutical industry says will result in a loss of profits that will force them to pull back on developing groundbreaking new treatments. The Biden administration's d

Source: aol.com
Analysis-Stelara patent deal puts J&J back on path to $57 billion 2025 revenue forecast - Vimarsana News

Analysis-Stelara patent deal puts J&J back on path to $57 billion 2025 revenue forecast

Johnson & Johnson's legal settlement with Amgen Inc to delay a biosimilar version of its blockbuster psoriasis treatment Stelara until January 2025 could make the drug a larger contributor to... | June 5, 2023

Drugmakers set strategy for legal fight against US pricing regulation - Vimarsana News

Drugmakers set strategy for legal fight against US pricing regulation

(Reuters) - Some of the world's biggest drugmakers are laying legal groundwork to fight the U.S. plan to negotiate drug prices for its Medicare health coverage, including the argument that a ban against speaking about these talks violates constitutional rights, according to six industry sources. | 06:17am

Moderna beats COVID vaccine sales expectations as deferred revenue rolls in - Vimarsana News

Moderna beats COVID vaccine sales expectations as deferred revenue rolls in

Moderna Inc on Thursday reported stronger-than-expected sales of $1.9 billion for its COVID-19 vaccine in the first quarter, driven by a surge of revenue deferred from 2022, but left its 2023... | May 4, 2023

Novavax cut $50 million in costs, plans to slash more, CEO says - Vimarsana News

Novavax cut $50 million in costs, plans to slash more, CEO says

Novavax Inc cut about $50 million in costs in the first quarter of 2023 and plans to slash more, Chief Executive John Jacobs said in an interview on Wednesday.... | April 12, 2023